Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07195656 · ClinicalTrials.gov registry record · NA
Evaluation of a Non-Implanted Electrical Stimulation Device for Overactive Bladder (OAB)
A NA study of Overactive Bladder (OAB), sponsored by FemPulse Corporation.
- Recruiting
- Registry status
- NA
- Development phase
- 151
- Enrollment target
- 15
- Study locations
NCT07195656: Recruiting NA study of Overactive Bladder (OAB), sponsored by FemPulse Corporation.
NCT07195656 is a NA study of Overactive Bladder (OAB) that is actively recruiting participants, run by FemPulse Corporation. The registered enrollment target is 151 participants, below the 270-participant average among 7 other Overactive Bladder (OAB) trials with a reported enrollment target (44% lower). The trial reports 15 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07195656, a NA study of Overactive Bladder (OAB), is actively recruiting participants, sponsored by FemPulse Corporation.
- RECRUITING
- Registry status
- NA
- Development phase
- 151 participants
- Enrollment target
- 15
- Study locations
Study Summary
A study to evaluate the safety and effectiveness of FemPulse System
Primary Outcome
Difference in mean change between device and medication groups in number of voids per day (VPD)
Conditions Studied
Interventions
- DEVICE Device Group
- DRUG Medication Group
Study Locations (15)
California
- Cedars Sinai - Beverly Hills
- UCLA - Los Angeles
- UC Irvine - Orange
- Stanford - Palo Alto
- USCD - San Diego
Florida
- Holy Cross Medical Group - Women's Center - Fort Lauderdale
Illinois
- Comprehensive Urologic - Barrington
Kentucky
- University of Louisville - Louisville
Maryland
- Chesapeake Urology - Owings Mills
Minnesota
- Minnesota Urology - Woodbury
Nebraska
- Adult & Pediatric Urology - Omaha
North Carolina
- Atrium Health - Charlotte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 151 participants |
| Start Date | 2025-09-30 |
| Est. Completion | 2027-12-31 |
| Phase | NA |
What NCT07195656 shows while recruiting
NCT07195656 is an interventional study that assigns participants to a tested intervention. The registered 151 participants enrollment target is mid-sized for trials with a published cap, below the 270-participant average among 7 other Overactive Bladder (OAB) trials with a reported enrollment target (44% lower).
The record links to 1 condition, with Overactive Bladder (OAB) appearing as the primary indexed condition, and to 2 interventions - of which Device Group is the first listed.
NCT07195656 lists 15 locations in 11 states (California, Florida, Illinois).
Frequently Asked Questions
What is clinical trial NCT07195656 about?
NCT07195656 is a clinical study titled "Evaluation of a Non-Implanted Electrical Stimulation Device for Overactive Bladder (OAB)". A study to evaluate the safety and effectiveness of FemPulse System
What is the current status of trial NCT07195656?
This trial is currently recruiting. It is a NA study. The enrollment target is 151 participants. The study started on 2025-09-30. Estimated completion is 2027-12-31.
What conditions does trial NCT07195656 study?
This clinical trial studies the following conditions: Overactive Bladder (OAB).
What interventions are being tested in trial NCT07195656?
The interventions under investigation include: Device Group (DEVICE), Medication Group (DRUG).
Who is sponsoring clinical trial NCT07195656?
This trial is sponsored by FemPulse Corporation, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07195656 being conducted?
This trial has 15 study locations across California, Florida, Illinois, Kentucky, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Overactive Bladder (OAB)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluating Pumpkin Seed Oil Extract Supplementation on Bladder Function
RECRUITING · NA
-
PMCF Study of the Axonics SNM System Model 5101 (R20)
RECRUITING · NA
-
Detrusor Nerve Radiofrequency Ablation for Overactive Bladder in Women
RECRUITING · NA
-
APPROVE Trial: Evaluating a Prescription Digital Therapeutic for Treatment of OAB in Women
RECRUITING · NA
-
Zinc Supplementation With Botulinum Toxin for Overactive Bladder
RECRUITING · Phase 2
-
Assessing the Genitourinary Microbiome of Women With Overactive Bladder Undergoing Onabotulinum Toxin Type A Intradetrusor Injections
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01409161 · 151 participants · Phase 2
Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
- NCT04245397 · 151 participants · Phase 1
Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome
- NCT05761223 · 151 participants · Phase 1
A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849
- NCT03328078 · 152 participants · Phase 1
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI